Get to know our clinical trials
Phase II clinical trial to evaluate the efficacy and safety of Raludotatug Deruxtecan (R-DXd) in advanced or metastatic solid tumors
THE MAIN OBJECTIVE IS TO EVALUATE THE EFFICACY OF R-DXD TREATMENT AS MEASURED BY ORR AS ASSESSED BY THE INVESTIGATOR.
Technical Summary
- PHASE II, MULTICENTER, OPEN-LABEL, PANTUMORAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RALUDOTATUG DERUXTECAN (R-DXD) IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
- Code EudraCT: 2024-513307-13-00
- Protocol number: DS6000-126
- Promoter: Daiichi Sankyo Inc
- Molecule/Drug: Raludotaug deruxtecan
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial

Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.